Real-World Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Early-Stage Non-Small-Cell Lung Cancer
The prognosis of early non-small-cell lung cancer (eNSCLC) remains poor. An understanding of current therapies and outcomes can provide insights into how novel therapies can be integrated into clinics. We conducted a large, retrospective, population-based cohort study of patients with de novo eNSCLC...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/31/1/30 |
| _version_ | 1797344388656922624 |
|---|---|
| author | Dylan E. O’Sullivan Devon J. Boyne Chelsea Ford-Sahibzada Jessica A. Inskip Christopher J. Smith Kaushik Sripada Darren R. Brenner Winson Y. Cheung |
| author_facet | Dylan E. O’Sullivan Devon J. Boyne Chelsea Ford-Sahibzada Jessica A. Inskip Christopher J. Smith Kaushik Sripada Darren R. Brenner Winson Y. Cheung |
| author_sort | Dylan E. O’Sullivan |
| collection | DOAJ |
| description | The prognosis of early non-small-cell lung cancer (eNSCLC) remains poor. An understanding of current therapies and outcomes can provide insights into how novel therapies can be integrated into clinics. We conducted a large, retrospective, population-based cohort study of patients with de novo eNSCLC (stages IB, IIA, IIB, and IIIA) diagnosed in Alberta, Canada, between 2010 and 2019. The primary objectives were to describe treatment patterns and survival outcomes among patients with eNSCLC. A total of 5126 patients with eNSCLC were included. A total of 45.3% of patients were referred to a medical oncologist, ranging from 23.7% in stage IB to 58.3% in IIIA. A total of 23.6% of patients initiated systemic therapy (ST), ranging from 3.5% in stage IB to 38.5% in IIIA. For stage IIB and IIIA individuals who received surgery, adjuvant ST was associated with a decreased likelihood of death (hazard ratios (HR) of 0.77 (95% CI: 0.56–1.07) and 0.69 (95% CI: 0.54–0.89), respectively). In a Canadian real-world setting, stage IIB and IIIA patients who received adjuvant ST tended to have better survival than patients who did not, but future studies that provide adjustment of additional confounders are warranted. Examining referral pathways that account for disparities based on age, sex, and comorbidities in the real world would also provide further insights. |
| first_indexed | 2024-03-08T11:01:41Z |
| format | Article |
| id | doaj.art-f9486525b3da431ea9bbe60f8f56da70 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-08T11:01:41Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-f9486525b3da431ea9bbe60f8f56da702024-01-26T15:58:23ZengMDPI AGCurrent Oncology1198-00521718-77292024-01-0131144746110.3390/curroncol31010030Real-World Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Early-Stage Non-Small-Cell Lung CancerDylan E. O’Sullivan0Devon J. Boyne1Chelsea Ford-Sahibzada2Jessica A. Inskip3Christopher J. Smith4Kaushik Sripada5Darren R. Brenner6Winson Y. Cheung7Department of Oncology, University of Calgary, Calgary, AB T2N 1N4, CanadaDepartment of Oncology, University of Calgary, Calgary, AB T2N 1N4, CanadaDepartment of Community Health Sciences, University of Calgary, Calgary, AB T2N 1N4, CanadaHoffmann-La Roche Limited, Mississauga, ON L5N 5M8, CanadaHoffmann-La Roche Limited, Mississauga, ON L5N 5M8, CanadaHoffmann-La Roche Limited, Mississauga, ON L5N 5M8, CanadaDepartment of Oncology, University of Calgary, Calgary, AB T2N 1N4, CanadaDepartment of Oncology, University of Calgary, Calgary, AB T2N 1N4, CanadaThe prognosis of early non-small-cell lung cancer (eNSCLC) remains poor. An understanding of current therapies and outcomes can provide insights into how novel therapies can be integrated into clinics. We conducted a large, retrospective, population-based cohort study of patients with de novo eNSCLC (stages IB, IIA, IIB, and IIIA) diagnosed in Alberta, Canada, between 2010 and 2019. The primary objectives were to describe treatment patterns and survival outcomes among patients with eNSCLC. A total of 5126 patients with eNSCLC were included. A total of 45.3% of patients were referred to a medical oncologist, ranging from 23.7% in stage IB to 58.3% in IIIA. A total of 23.6% of patients initiated systemic therapy (ST), ranging from 3.5% in stage IB to 38.5% in IIIA. For stage IIB and IIIA individuals who received surgery, adjuvant ST was associated with a decreased likelihood of death (hazard ratios (HR) of 0.77 (95% CI: 0.56–1.07) and 0.69 (95% CI: 0.54–0.89), respectively). In a Canadian real-world setting, stage IIB and IIIA patients who received adjuvant ST tended to have better survival than patients who did not, but future studies that provide adjustment of additional confounders are warranted. Examining referral pathways that account for disparities based on age, sex, and comorbidities in the real world would also provide further insights.https://www.mdpi.com/1718-7729/31/1/30early-stage non-small-cell lung cancerpopulation-based cohort studyreal-world data |
| spellingShingle | Dylan E. O’Sullivan Devon J. Boyne Chelsea Ford-Sahibzada Jessica A. Inskip Christopher J. Smith Kaushik Sripada Darren R. Brenner Winson Y. Cheung Real-World Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Early-Stage Non-Small-Cell Lung Cancer Current Oncology early-stage non-small-cell lung cancer population-based cohort study real-world data |
| title | Real-World Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Early-Stage Non-Small-Cell Lung Cancer |
| title_full | Real-World Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Early-Stage Non-Small-Cell Lung Cancer |
| title_fullStr | Real-World Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Early-Stage Non-Small-Cell Lung Cancer |
| title_full_unstemmed | Real-World Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Early-Stage Non-Small-Cell Lung Cancer |
| title_short | Real-World Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Early-Stage Non-Small-Cell Lung Cancer |
| title_sort | real world treatment patterns clinical outcomes and healthcare resource utilization in early stage non small cell lung cancer |
| topic | early-stage non-small-cell lung cancer population-based cohort study real-world data |
| url | https://www.mdpi.com/1718-7729/31/1/30 |
| work_keys_str_mv | AT dylaneosullivan realworldtreatmentpatternsclinicaloutcomesandhealthcareresourceutilizationinearlystagenonsmallcelllungcancer AT devonjboyne realworldtreatmentpatternsclinicaloutcomesandhealthcareresourceutilizationinearlystagenonsmallcelllungcancer AT chelseafordsahibzada realworldtreatmentpatternsclinicaloutcomesandhealthcareresourceutilizationinearlystagenonsmallcelllungcancer AT jessicaainskip realworldtreatmentpatternsclinicaloutcomesandhealthcareresourceutilizationinearlystagenonsmallcelllungcancer AT christopherjsmith realworldtreatmentpatternsclinicaloutcomesandhealthcareresourceutilizationinearlystagenonsmallcelllungcancer AT kaushiksripada realworldtreatmentpatternsclinicaloutcomesandhealthcareresourceutilizationinearlystagenonsmallcelllungcancer AT darrenrbrenner realworldtreatmentpatternsclinicaloutcomesandhealthcareresourceutilizationinearlystagenonsmallcelllungcancer AT winsonycheung realworldtreatmentpatternsclinicaloutcomesandhealthcareresourceutilizationinearlystagenonsmallcelllungcancer |